Sign up to save your podcasts
Or
Share Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.
View all episodes
By The Uromigos
4.9
5555 ratings
Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.
More shows like The Uromigos
View all
JAMA Editors' Summary
140 Listeners
NEJM This Week
318 Listeners
AFP: American Family Physician Podcast
700 Listeners
JAMA Clinical Reviews
499 Listeners
Prostate Cancer Update
14 Listeners
ASCO Daily News
58 Listeners
White Coat Investor Podcast
2,445 Listeners
The Curbsiders Internal Medicine Podcast
3,349 Listeners
The Peter Attia Drive
9,202 Listeners
Annals On Call Podcast
196 Listeners
The Clinical Problem Solvers
512 Listeners
GU Cast | Urology Podcast
2 Listeners
BioCentury This Week
34 Listeners
Two Onc Docs
190 Listeners
The View on GU | with Lalani and Wallis
2 Listeners